{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:35:14Z","timestamp":1773970514490,"version":"3.50.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the efficacy and safety of Iguratimod (IGU) intervention in the treatment of Ankylosing Spondylitis (AS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used computer to search literature databases, collected randomized controlled trials (RCTs) related to IGU treatment of AS, and searched the relevant literature in each database until Sep. 2022. Two researchers independently carried out literature screening, data extraction, and evaluation and analysis of the risk of bias in the included studies, and then used Rev Man5.3 software for meta-analysis. The protocol is CRD42020220798.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 10 RCTs involves in 622 patients were collected. The statistical analysis showed that IGU can decrease the BASDAI score (SMD -1.62 [-2.20, -1.05], P&amp;lt;0.00001. Quality of evidence: low), the BASFI score (WMD -1.30 [-1.48, -1.12], P&amp;lt;0.00001. Quality of evidence: low) and the VAS (WMD -2.01 [-2.83, -1.19], P&amp;lt;0.00001. Quality of evidence: very low). Meanwhile, the addition of IGU into the conventional therapy would not increase the adverse events (RR 0.65 [0.43, 0.98], P=0.04. Quality of evidence: moderate).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IGU may be an effective and safe intervention for AS. <\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?<\/jats:uri>, identifier CRD42020220798.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.993860","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T06:10:45Z","timestamp":1677823845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of Iguratimod in the treatment of Ankylosing Spondylitis: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhiyong","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wensa","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiapeng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"B1","article-title":"Ankylosing spondylitis: an update","volume":"42","author":"Golder","year":"2003","journal-title":"Aust Fam Physician"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11882-014-0489-6","article-title":"Update on ankylosing spondylitis: Current concepts in pathogenesis","volume":"15","author":"Smith","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200307000-00004","article-title":"Molecular and cellular biology of new bone formation: Insights into the ankylosis of ankylosing spondylitis","volume":"15","author":"Zhang","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"F1000 Faculty Rev-1512","DOI":"10.12688\/f1000research.14956.1","article-title":"Recent advances in ankylosing spondylitis: Understanding the disease and management","volume":"7","author":"Garcia-Montoya","year":"2018","journal-title":"F1000Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.015","article-title":"The classification and diagnostic criteria of ankylosing spondylitis","author":"Raychaudhuri","year":"2014","journal-title":"J Autoimmun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0000000000000443","article-title":"NSAIDs and cardiovascular risk","author":"Marsico","year":"2017","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18433\/j3vw2f","article-title":"Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications","volume":"16","author":"Harirforoosh","year":"2013","journal-title":"J Pharm Pharm Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.3390\/ijms19082199","article-title":"Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-\u03b1 on the liver","volume":"19","author":"Lopetuso","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04986-9","article-title":"Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"39","author":"Shrestha","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10875-011-9542-6","article-title":"PingCombined treatment of etanercept and MTX reverses Th1\/Th2, Th17\/Treg imbalance in patients with rheumatoid arthritis","volume":"31","author":"Lina","year":"2011","journal-title":"J Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7648","article-title":"Iguratimod prevents ovariectomyinduced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferatoractivated receptorgamma.Mol","author":"Wu","year":"2017","journal-title":"Med Rep.16"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13463","article-title":"Huang.Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9.Int","volume":"22","author":"Zhao","year":"2019","journal-title":"J Rheumatol Dis"},{"key":"B15","article-title":"Observation on the clinical effect of iguratimod in the treatment of refractory ankylosing spondylitis","volume":"26","author":"Qiu","year":"2016","journal-title":"J Jiangsu Univ (Medical Edition)"},{"key":"B16","first-page":"163","article-title":"Efficacy of iguratimod combined with methotrexate in the treatment of refractory ankylosing spondylitis and its effect on serum SOD and CTX-I levels in patients","volume":"29","author":"Yuan","year":"2020","journal-title":"J Pharm Epidemiol"},{"key":"B17","article-title":"Efficacy of iguratimod combined with etanercept in the treatment of ankylosing spondylitis","volume":"20","author":"Pang","year":"2020","journal-title":"J Trop Med"},{"key":"B18","first-page":"9","article-title":"Preliminary observation on the treatment of ankylosing spondylitis with iguratimod","volume":"12","author":"Lin","year":"2019","journal-title":"J Clin Rational Use"},{"key":"B19","article-title":"Study on the efficacy and safety of iguratimod in the treatment of ankylosing spondylitis","volume":"50","author":"Xu","year":"2019","journal-title":"New Med"},{"key":"B20","article-title":"Observation on the efficacy of iguratimod in the treatment of ankylosing spondylitis","volume":"27","author":"Zeng","year":"2016","journal-title":"Hainan Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.678864","article-title":"Randomised, double-blind, placebo-controlled study of iguratimod in the treatment of active spondyloarthritis","volume":"8","author":"Li","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-4985.2021.02.011","article-title":"Observation on the clinical effect of iguratimod in the treatment of axial spondyloarthritis","volume":"18","author":"Bai","year":"2021","journal-title":"Chin Med Innovation"},{"key":"B23","article-title":"Observation of the curative effect of iguratimod in the treatment of ankylosing spondylitis","volume":"34","author":"Li","year":"2021","journal-title":"J Med Theor Prac"},{"key":"B24","article-title":"Efficacy of iguratimod combined with celecoxib in the treatment of ankylosing spondylitis","volume":"35","author":"Zhang","year":"2022","journal-title":"J Med Inf"},{"key":"B25","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane handbook or systematic reviews of interventions version 6.1.0","author":"Deeks","year":"2020"},{"key":"B26","article-title":"Chapter 9: Analyzing data and undertaking meta-analyses","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Deeks","year":"2020"},{"key":"B27","article-title":"Observation on the short-term curative effect of iguratimod in the treatment of ankylosing spondylitis","volume":"34","author":"Huang","year":"2018","journal-title":"Chin Community Physician"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1390150","article-title":"Is iguratimod effective in refractory axial spondyloarthritis","volume":"47","author":"Luo","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.19842\/j.cnki.issn.0253-9934.2021.06.013","article-title":"Observation on the clinical efficacy of iguratimod in the treatment of axial spondyloarthritis","volume":"44","author":"Xu","year":"2021","journal-title":"Shanghai Med J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.56","article-title":"Pathogenesis of ankylosing spondylitis - recent advances and future directions","volume":"13","author":"Ranganathan","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11926-019-0856-3","article-title":"The pathogenesis of ankylosing spondylitis: An update","author":"Pedersen","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: From pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/art.40175","article-title":"Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis","volume":"69","author":"Ranganathan","year":"2017","journal-title":"Arthritis Rheum"},{"key":"B36","doi-asserted-by":"publisher","first-page":"R136","DOI":"10.1186\/ar2554","article-title":"T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis","volume":"10","author":"Du","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300832","article-title":"A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide","volume":"191","author":"Luo","year":"2013","journal-title":"J Immunol"},{"key":"B38","article-title":"Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells","volume":"28","author":"Kohno","year":"2001","journal-title":"J Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.intimp.2016.03.038","article-title":"Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-\u03baB and MAPK pathways","volume":"35","author":"Gan","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7648","article-title":"Iguratimod prevents ovariectomyinduced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferatoractivated receptor\u03b3","volume":"16","author":"Wu","year":"2017","journal-title":"Mol Med Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7648","article-title":"Iguratimod prevents ovariectomy\u2212induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator\u2212activated receptor\u2212\u03b3","volume":"16","author":"Wu","year":"2017","journal-title":"Mol Med Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.14715\/cmb\/2016.62.13.8","article-title":"BiEffect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1beta-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis","volume":"62","author":"Wang","year":"2016","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"B43","article-title":"Clinical observation of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis","volume":"28","author":"Ren","year":"2017","journal-title":"China Pharm"},{"key":"B44","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.intimp.2016.03.038","article-title":"Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-kappaB and MAPK pathways","volume":"35","author":"Gan","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05968-1","article-title":"Biomarkers in axial spondyloarthritis and low back pain: A comprehensive review","volume":"41","author":"Reveille","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.intimp.2012.03.003","article-title":"T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro","volume":"13","author":"Du","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(02)02754-7","article-title":"A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo","volume":"299","author":"Kuriyama","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","article-title":"The novel zinc finger-containing tranion factor osterix is required for osteoblast differentiation and bone formation","volume":"108","author":"Nakashima","year":"2002","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4901591","DOI":"10.1155\/2018\/4901591","article-title":"T-614 promotes osteoblastic cell differentiation by increasing Dlx5 expression and regulating the activation of p38 and NF-\u03baB","volume":"2018","author":"Song","year":"2018","journal-title":"BioMed Res Int"},{"key":"B50","first-page":"6","article-title":"Modulation of Th17 cells and treg cell imbalance in patients with rheumatoid arthritis by iguratimod","volume":"31","author":"Wang","year":"2018","journal-title":"Chin J Med Equip"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109704","article-title":"Molecular mechanisms and clinical application of iguratimod: A review","volume":"122","author":"Jiang","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.924730","article-title":"A systematic review and meta-analysis of 19 randomized controlled trials of iguratimod combined with other therapies for sjogren's syndrome","volume":"13","author":"Zeng","year":"2022","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"A772","DOI":"10.1016\/j.jval.2014.08.321","article-title":"The research of effects of Iguratimod(T-614) on the apoptosis of peripheral blood mononuclear cell and TH1 in rheumatoid arthritis","volume":"17","author":"Liu","year":"2014","journal-title":"Value Health"},{"key":"B54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-019-1874-2","article-title":"Iguratimod represses b cell terminal differentiation linked with the inhibition of PKC\/EGR1 axis","volume":"21","author":"Ye","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B55","volume-title":"GRADEpro guideline development tool [Software]","year":"2015"},{"key":"B56","volume-title":"GRADE handbook for grading quality of evidence and strength of recommendations. updated October 2013","author":"Sch\u00fcnemann","year":"2013"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.993860\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T06:10:58Z","timestamp":1677823858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.993860\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2023.993860"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.993860","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"article-number":"993860"}}